Reading CTXR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CTXR free→Reading CTXR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CTXR free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality cannot be assessed as the company was unprofitable over the past year. Peer multiples imply a price about 82% above where it trades (it looks cheap on this basis), and the read is cheap, value-trap risk, as it trades below peer multiples while recent financials are weak. Key factors to watch include the performance of sector bellwethers and CTXR's upcoming earnings results. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $0.54. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $0.54 CTXR trades at 2× p/s, below its 10× p/s peer median. Our $3.11 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price sits about 82% below a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.57x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates.
12 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.00 → $-0.36. 0 raised, 0 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$365.
How much price usually moves either way.
On a bad day, this stock has moved -$899.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,615.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Management fell by 11.5 points (from 52.7 to 41.2).
Management fell. This indicates a decline in management quality. The company remains loss-making and has weak recent financial performance. The sector backdrop is a headwind, which may affect performance.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CTXR yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 15, 2026, Citius Pharmaceuticals, Inc. issued a press release announcing its results of operations for the second quarter of fiscal 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subje…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
A side-by-side read on sector standing, valuation, and risk versus peers.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CTXR CITIUS PHARMACEUTICALS INC | Typical Show detailsSector percentile: 41 of 100 | inexpensive | high |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Citius Pharmaceuticals is actively engaging in mergers and acquisitions to strengthen its position.
Stated in 2 of last 2 quarters. Citius Pharmaceuticals has been actively engaging in M&A activities, as evidenced by the Material Definitive Agreement entered on May 4, 2026. However, financials show a net income decline from -$9.4M in 2026-Q1 to -$28.1M in 2026-Q2, indicating limited progress in financial improvement from these activities.
“Citius entered into a Material Definitive Agreement related to M&A activity.”
“Citius engaged in M&A activity as noted in the April 24, 2026 report.”
Citius Pharmaceuticals is addressing compliance issues related to Nasdaq listing requirements.
Newly stated in 2026-Q1. Citius Pharmaceuticals received a notice from Nasdaq regarding non-compliance with the $1.00 bid price rule. The company has not yet demonstrated progress in addressing this regulatory issue, as financials show continued net losses, with net income at -$28.1M in 2026-Q2.
“Nasdaq notified Citius of non-compliance with the $1.00 bid price rule.”
Citius Pharmaceuticals aims to improve its financial performance amidst ongoing losses.
Stated in 3 of last 3 quarters. Despite efforts to improve financial performance, Citius Pharmaceuticals' net income declined from -$9.4M in 2026-Q1 to -$28.1M in 2026-Q2, indicating limited progress in reversing financial losses.
“Citius reported a net income loss of $28.1M.”
Entry into a Material Definitive Agreement. On May 4, 2026, in connection with an equity financing transaction and debt facility by Citius Oncology, Inc. (“Citius Oncology”), the majority-owned subsidiary of Citius Pharmaceuticals, Inc. (the “Company”), the Company and Citius Oncology entered into a Third Amendment to Promissory Note (the “Third Amendment”), which amends the promissory note, dated August 16, 2024, as previously amended on September 10, 2025 and December 10, 2025, issued by th…
of the Current Report on Form 8 K filed by the Company on April 24, 2026 is incorporated by reference into this
Entry into a Material Definitive Agreement. On April 23, 2026, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 4,730,457 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 345,686 shares of common stock (the “Pre-funded Warr…
Unregistered Sales of Equity Securities. As previously disclosed, Citius Pharmaceuticals, Inc. (the “Company”) closed a registered direct offering of common stock and a concurrent private placement of pre-funded warrants, common warrants and placement agent warrants. The disclosure set forth under
“Citius reported a net income loss of $9.4M.”
“Citius reported a net income loss of $8.7M.”